{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:44:17Z","timestamp":1785224657931,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41401-025-01605-8","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T07:09:10Z","timestamp":1752476950000},"page":"3314-3326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Co-delivery of shikonin and JQ1 inhibits triple-negative breast tumor progression and lung metastasis through inhibition of epithelial-mesenchymal transition and vasculogenic mimicry"],"prefix":"10.1038","volume":"46","author":[{"given":"Xing-yu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika Ramdas","family":"Kalambhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-xi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-wen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704\u201315.","journal-title":"Cell"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275\u201392.","journal-title":"Cell"},{"key":"1605_CR5","doi-asserted-by":"crossref","unstructured":"Liu S, Kang M, Ren Y, Zhang Y, Ba Y, Deng J, et al. The interaction between vasculogenic mimicry and the immune system: mechanistic insights and dual exploration in cancer therapy. Cell Prolif. 2025:e13814.","DOI":"10.1111\/cpr.13814"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41420-023-01423-z","volume":"9","author":"B Cheng","year":"2023","unstructured":"Cheng B, Xie M, Zhou Y, Li T, Liu W, Yu W, et al. Vascular mimicry induced by m6A mediated IGFL2-AS1\/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. Cell Death Discov. 2023;9:121.","journal-title":"Cell Death Discov"},{"key":"1605_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03077-0","volume":"22","author":"J Wang","year":"2024","unstructured":"Wang J, Chen Z, Zhao P, Wang Y, Chen J, Lin Q. PDGFR-alpha shRNA-polyplex for uveal melanoma treatment via EMT mediated vasculogenic mimicry interfering. J Nanobiotechnol. 2024;22:797.","journal-title":"J Nanobiotechnol"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871\u201390.","journal-title":"Cell"},{"key":"1605_CR10","doi-asserted-by":"crossref","unstructured":"Wei X, Ge Y, Zheng Y, Zhao S, Zhou Y, Chang Y, et al. Hybrid EMT phenotype and cell membrane tension promote colorectal cancer resistance to ferroptosis. Adv Sci. 2025;12:e2413882.","DOI":"10.1002\/advs.202413882"},{"key":"1605_CR11","doi-asserted-by":"crossref","unstructured":"Chang TM, Fang WY, Hsu HP, Chu PY, Jiang SS, Huang KW, et al. PCK2 promotes invasion and epithelial-to-mesenchymal transition in triple-negative breast cancer by promoting TGF-beta\/SMAD3 signaling through inhibiting TRIM67-mediated SMAD3 ubiquitination. Cancer Biol Ther. 2025;26:2478670.","DOI":"10.1080\/15384047.2025.2478670"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/abbs\/gmaa014","volume":"52","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang J, Zhou H, Liu G, Li Q. Rho kinase mediates transforming growth factor-beta1-induced vasculogenic mimicry formation: involvement of the epithelial-mesenchymal transition and cancer stemness activity. Acta Biochim Biophys Sin. 2020;52:411\u201320.","journal-title":"Acta Biochim Biophys Sin"},{"key":"1605_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31615-y","volume":"8","author":"X Zhao","year":"2018","unstructured":"Zhao X, Zhu Y, Hu J, Jiang L, Li L, Jia S, et al. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis. Sci Rep. 2018;8:14517.","journal-title":"Sci Rep"},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jconrel.2022.12.003","volume":"353","author":"Y Huang","year":"2023","unstructured":"Huang Y. Targeting glycolysis for cancer therapy using drug delivery systems. J Control Rel. 2023;353:650\u201362.","journal-title":"J Control Rel"},{"key":"1605_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/cbin.11247","volume":"44","author":"X Li","year":"2020","unstructured":"Li X, Zeng X. Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b\/SMAD7\/TGF-beta signaling pathway. Cell Biol Int. 2020;44:467\u201376.","journal-title":"Cell Biol Int"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-023-02688-z","volume":"42","author":"L Long","year":"2023","unstructured":"Long L, Xiong W, Lin F, Hou J, Chen G, Peng T, et al. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery. J Exp Clin Cancer Res. 2023;42:117.","journal-title":"J Exp Clin Cancer Res"},{"key":"1605_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120604","volume":"269","author":"N Qiu","year":"2021","unstructured":"Qiu N, Liu Y, Liu Q, Chen Y, Shen L, Hu M, et al. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Biomaterials. 2021;269:120604.","journal-title":"Biomaterials"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/onc.2016.184","volume":"36","author":"LL da Motta","year":"2017","unstructured":"da Motta LL, Ledaki I, Purshouse K, Haider S, De Bastiani MA, Baban D, et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene. 2017;36:122\u201332.","journal-title":"Oncogene"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Tang Y, Fang Y, Zhang M, Wang H, He Z, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of Shikonin\/JQ1. Nano Lett. 2019;19:2935\u201344.","journal-title":"Nano Lett"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni T, Mavrianou N, Gavalas NG, Tzannis K, Arapinis C, Liontos M, et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signalling pathway in ovarian cancer. Eur J Cancer. 2020;126:125\u201335.","journal-title":"Eur J Cancer"},{"key":"1605_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2018.12.002","volume":"127","author":"S Song","year":"2019","unstructured":"Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W, et al. Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-beta-induced endothelial-mesenchymal transition and cardiac fibrosis. J Mol Cell Cardiol. 2019;127:83\u201396.","journal-title":"J Mol Cell Cardiol"},{"key":"1605_CR22","first-page":"1030","volume":"11","author":"M Zhuo","year":"2019","unstructured":"Zhuo M, Yuan C, Han T, Hu H, Cui J, Jiao F, et al. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1\/2-MMP-2\/9 signaling pathway both in vitro and in vivo. Am J Transl Res. 2019;11:1030\u20139.","journal-title":"Am J Transl Res"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u2013W14.","journal-title":"Nucleic Acids Res"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1605_CR25","doi-asserted-by":"crossref","unstructured":"Perez-Tomas R, Perez-Guillen I. Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers. 2020;12:3244.","DOI":"10.3390\/cancers12113244"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"1605_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155504","volume":"128","author":"C Wang","year":"2024","unstructured":"Wang C, Zhang M, Peng J, Zhang M, Lu C, Qi X, et al. Combining cisplatin with Pinellia pedatisecta Schott lipid-soluble extract induces tumor immunogenic cell death in cervical cancer. Phytomedicine. 2024;128:155504.","journal-title":"Phytomedicine"},{"key":"1605_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"1605_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2016.09.012","volume":"383","author":"J Yang","year":"2016","unstructured":"Yang J, Lu Y, Lin YY, Zheng ZY, Fang JH, He S, et al. Vascular mimicry formation is promoted by paracrine TGF-beta and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma. Cancer Lett. 2016;383:18\u201327.","journal-title":"Cancer Lett"},{"key":"1605_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1605_CR32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN guidelines(R) insights: breast cancer, version 4.2023. J Natl Compr Canc Netw. 2023;21:594\u2013608.","journal-title":"J Natl Compr Canc Netw"},{"key":"1605_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1605_CR34","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00018-016-2166-5","volume":"73","author":"C Belgiovine","year":"2016","unstructured":"Belgiovine C, D\u2019Incalci M, Allavena P, Frapolli R. Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci. 2016;73:2411\u201324.","journal-title":"Cell Mol Life Sci"},{"key":"1605_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"1605_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01605-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:06:16Z","timestamp":1764180376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01605-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01605-8","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}